MD Anderson researchers present promising clinical trial results at AACR 2025

Researchers at the University of Texas MD Anderson Cancer Center will present promising clinical trial results in three mini -deposits in the American Association for Cancer Research (AACR) Annual Meeting 2025. The results include the personalized treatment of the combination combination for large intestinal cancer, the use of radiotherapy to av systemic kidney cancer, as well as mutant engineering in colorectal cancer.

In addition to these attempts, the upcoming press releases will have significant summaries of the oral and plenary session. More information about all annual content of MD Anderson AACR meetings can be found at mdanderson.org/aacr.

Personalized with or without immunotherapy It is safe for patients with subtype of metastatic colorectal cancer (CT012 abstract)

Patients with microsatellite metastatic colorectal cancer (MSS MCRC) have poor results and limited treatment options after standard chemotherapy failure, partly due to the immune “cold” tumor microenvil. Scientists led by Saurav Daniel Haldar, MD and Michael Overman, developed a personalized vaccine platform called NeoAg-Vax, which uses bioinformatic tools and sequencing to supply up to 10 proteins from cancer directed to a specific combination of each patient’s mutation. In this feasibility study and phases, scientists combined a personalized vaccine with pembrolyzumab immunotherapy in 28 MCRC patients. The personalized vaccine was safe and feasible for administration, which leads to strong immune answers in most patients vaccinated in this study. Scientists also characterized the composition of immune cells in patient tumors, ensuring molecular insight into the immune micro -environment that could affect future therapeutic approaches. Haldar will present the results on April 27.

Metastasis-Izpened radiation therapy avoids toxicity of systemic therapy in patients with cellular cells (abstract CT132)

Systemic therapies used in patients with metastatic cellular cellular cancer (CCRCC), such as tyrosine kinase immunotherapy and inhibitors, are associated with a high toxicity indicator. Radiotherapy focused on metastases may limit side effects, but there are no established biomarkers to identify patients who will most likely react. That is why scientists led by Chada Tang, MD and Pavlos Msouel, Ph.D., conducted a prospective test of phase II examining the therapy focused on metastases without systemic therapy in 121 patients with aolometastatic CCRCC. The median experience free from progression (PFS) was 18 months, with a median 34-month experience without therapy (STF). Importantly, the overall experience (OS) was not threatened, with OS 94% and 87% indicators after two and three years respectively. Scientists also tested a new DNA test of the circulating tumor (CTDNA) to detect a molecular residual disease (MRD). Patients who were MRD- compared to MRD+ at the beginning, had a Mediana STF of 54 months compared to 27 months. These discoveries show that radiotherapy focused on metastases can help patients avoid systemic therapies without prejudice to the results and that the CTDNA test is a useful personalized forecast biomarker For answers. Tang will present the results on April 28.

Exosomes provide genes of pancreatic cancer suppressors (CT265 abstract)

Mutations occur in more than 40% of pancreatic cancer cases, but Kras inhibitors have not brought permanent answers in patients, partly due to the immunosuppressive tumor microenota. Exosomes are small extracellular bubbles that can be designed to carry a small disturbing RNA (sirna), which will silence the genes specific to cancer cells. In the first in the human phase of escalation and, scientists led by Valerie Lebleu, MD, Ph.D., Shubham Pant, MD, Elizabeth Shpall, MD and Brandon Smaglo, MD, have examined the use of designed exosomes from bone cubes. Six of 12 patients receiving all doses of exosome had a stable disease in target changes and no toxicity limiting the dose was found. Scientists noticed a reduction in the circulating DNA after treatment. Further analysis showed that these exosomes will work well with an immune lock in order to reprogram the neoplasm microenvil and overcome the resistance to treatment, emphasizing the combination as a potential therapeutic strategy studied in the upcoming phase II study. Lebleu will present the results on April 29.

In addition, the CT267 summary contains data from early clinical trials from the ATR, Art0380 kinase inhibitor, in advanced solid tumors. This targeted therapy was initially discovered and developed by MD Anderson’s Therapeutics Discovery Division and licensed for Artios Pharma. Post -clinical and translation studies conducted by researchers in MD Anderson, published, showed strong anti -cancer activity and established an innovative approach to optimizing patients’ selection based on molecular tumor features.